Anti-Proteoglycan Antibody Development Services
Overview
Proteoglycans organize hydration, viscoelasticity, and growth-factor presentation across tissues, making them high-value biomarkers and intervention points. Their alterations track development, injury, and repair, underscoring translational relevance. Meanwhile, circulating autoantibody profiles are abundant and stable, enabling multiplexed detection paradigms that complement target-specific assays. Together, these insights justify focused antibody programs against proteoglycan core and neoepitopes.
Are you currently facing prolonged assay development, epitope masking on complex glycoconjugates, inconsistent specificity, or matrix-dependent performance? Anti-proteoglycan antibody development services at Creative Biolabs help deliver high-specificity, application-ready antibodies by combining glycan-aware antigen design, multi-platform discovery, and rigorous matrix validation to reduce rework and speed decisions.
We implement a comprehensive, glycan-aware strategy for anti-proteoglycan antibody development, as follows:
-
Glycan-Aware Antigen Engineering
Engineer immunogens that preserve or expose desired determinants: core-protein domains, defined GAG motifs, and protease-generated neoepitopes to track turnover. This deconvolutes total abundance from degradation activity.
-
Multi-Route Discovery & Selection
Run hybridoma, single-B-cell, and display-based discovery in parallel to capture diverse paratopes for large, heterogeneous PG targets. Layer high-throughput screening to prioritize clones with clean, application-matched behavior.
-
Matrix-Informed Screening
Screen from the outset in relevant matrices (serum, synovial fluid, conditioned media) to counter epitope masking and reduce off-target binding that only appears outside of buffer.
-
Epitope Mapping & Isotype Optimization
Map epitopes via peptide/fragment tiling and competition. Select formats (IgG, Fab, scFv, VHH) and isotypes aligned to IHC, ELISA, flow cytometry, IP, or functional blocking.
-
Developability & Stability Profiling
Profile aggregation, non-specific binding, pH/temperature robustness, and storage stability early to de-risk translation and ensure lot-to-lot consistency.
Learn How We Can Accelerate Your Research – Request a Consultation Today.
Service Portfolio
Anti-NG2 Antibody Development Service
We provide end-to-end development against the cell-surface proteoglycan CSPG4/NG2—from immunogen design using extracellular and CS-rich regions to multi-platform discovery (hybridoma, single-B-cell, display) with neural/tumor matrix–aware screening and integrated epitope mapping.
Anti-Versican Antibody Development Service
We provide isoform-aware development for the hyalectan versican (V0–V3), targeting G1/G3 domains and CS-rich regions to enable total, isoform-specific, and neoepitope-focused measurements with discovery and validation tuned to tissue and biofluid matrices.
Anti-Biglycan Antibody Development Service
We provide custom development to the SLRP biglycan, designing immunogens across LRR motifs to distinguish ECM-bound versus soluble pools, with discovery and orthogonal validation aligned to bone, cartilage, and inflammatory models.
Anti-Aggrecan Antibody Development Service
We provide antibodies to aggrecan core domains and degradation-associated neoepitopes, using synovial and cartilage matrix screening to support robust detection of total content and turnover in joint and cartilage research.
Anti-Neurocan Antibody Development Service
We provide CNS-focused development against neurocan, covering hyaluronan-binding and CS-bearing regions, with discovery and validation emphasizing brain tissue and CSF contexts to minimize matrix interference and support neurodevelopment and scarring studies.
Anti-Decorin Antibody Development Service
We provide antibodies to decorin for studies of fibrillogenesis, fibrosis, and tissue remodeling, employing core-protein immunogens (LRR scaffold and terminals) and matrix-aware screening to sharpen specificity in complex ECM settings.
Anti-Fibromodulin Antibody Development Service
We provide development targeting fibromodulin for tendon, ligament, and corneal research, selecting core-domain and modification-sensitive immunogens and confirming specificity with orthogonal assays in fibrous matrices.
Anti-Heparan Sulfate Proteoglycan Antibody Development Service
We provide development for heparan sulfate proteoglycans (e.g., syndecans, glypicans, perlecan), engineering core- and glycan-context immunogens, and using enzymatic/competition controls to verify HS-dependent recognition across relevant biological matrices.
What We Can Offer
Custom Antibody Generation
Custom antibodies against proteoglycan core domains, GAG-dependent determinants, and neoepitopes (research use only), delivered as purified IgG/Fab/scFv/VHH.
Epitope & Developability Dossier
Epitope mapping, cross-reactivity panels, and stability/developability data with buffer and storage recommendations.
Multiplex Panel Design
Optional multi-analyte panels integrating proteoglycan targets with complementary ECM and injury/repair markers for translational studies.
Format Engineering & Pilot Production
Rapid reformatting (IgG, Fab, scFv, VHH) with optional affinity maturation, buffer optimization, and small-batch production with full QC (purity, binding kinetics, endotoxin) ready for downstream validation.
Workflow
01Antigen strategy & design
Select recombinant domains, glycan-mimetic constructs, or protease-generated fragments. For degradation readouts, incorporate known cleavage motifs to expose neoepitopes indicative of disease activity.
02Immunization & discovery
Run parallel tracks (hybridoma, single-B-cell, display). Use staged boosts and decoy antigens to bias specificity away from conserved or glycan-nonspecific surfaces.
03Matrix-aware screening
Primary screens in relevant fluids/tissues filter clones susceptible to matrix interference. Secondary assays quantify specificity versus related ECM proteins and abundant serum components.
04Epitope mapping & functional profiling
Localize binding sites with fragment/peptide panels and competition assays. Where applicable, verify recognition of neoepitopes and quantify detection of catabolic fragments in biologic samples.
05Developability assessment
Evaluate aggregation risk, isoelectric point, non-specific binding, and stability under storage/assay conditions. Prioritize robust candidates for downstream use.
06Format engineering & scale-up
Reformat to IgG/Fab/scFv/VHH as needed. Produce pilot lots with QC (purity, endotoxin) and binding kinetics. Optimize buffers for your application.
Highlights
Glycan-Aware Design
Reduces epitope masking and improves performance in real matrices.
Neoepitope Precision
Sensitive readouts of proteoglycan turnover for remodeling and monitoring.
Multiplex-Ready Intelligence
Complements single-analyte assays to broaden decision support.
Publication
Proteoglycans are protein cores bearing glycosaminoglycan (GAG) chains that function as modular, matrix- and membrane-localized machines. Extracellular families include lecticans—aggrecan, versican, brevican—with bottlebrush architectures that bind hyaluronan via G1–G3 domains to sustain hydration and mechanics. Small leucine-rich proteoglycans (decorin, biglycan, lumican, fibromodulin) use horseshoe-shaped cores to orchestrate collagen assembly. At the cell surface, syndecans (transmembrane) and glypicans (GPI-anchored) position heparan sulfate chains to present growth factors. Diversity in GAG number, length, and sulfation (HS, CS/DS, KS) creates distinct binding landscapes, guiding interactions and informing epitope selection for antibody development.
Fig.1 Structural organization of proteoglycans.1
Customer Reviews
Cleaner degradation readouts in cartilage explants
“Using Creative Biolabs’ anti-proteoglycan antibody development services in our research has significantly improved catabolic fragment detection in our aggrecan assays.” [Spring], Dr. Ja*** Ko***
Consistent IHC in the injured spinal cord
“Using Creative Biolabs’ anti-proteoglycan antibody development services in our research has significantly improved CSPG4 staining reproducibility across fixation conditions.” [Autumn], Dr. Mi*** Al***
Matrix-tolerant ELISA in synovial fluid
“Using Creative Biolabs’ anti-proteoglycan antibody development services in our research has significantly improved quantitation with lower background versus our prior polyclonal mix.” [Winter], Dr. Le*** Sa***
FAQs
Which epitope types best track tissue remodeling?
Neoepitopes generated by protease cleavage are ideal for turnover; core-protein epitopes capture total abundance. Pairing both adds biological context.
How do you mitigate off-target binding in complex matrices?
We screen in real matrices from the outset, counter-screen against abundant ECM proteins/serum components, and confirm with orthogonal assays.
Can antibodies recognize glycan-dependent determinants?
Yes. We design immunogens to preserve glycan context or mimic GAG motifs, and validate with enzymatic or competition controls to prove dependence.
Extended Services
Custom polysaccharides (mg–g) with controlled composition, α/β linkage, branching, MW, and substitutions (e.g., sulfation). Chemical/enzymatic/chemoenzymatic routes for HS/CS/DS/KS mimetics, hyaluronan, dextran, pullulan, and chitosan. Optional tags and protein/carrier conjugation; microarray-ready. Delivered with QC (NMR, MS, HPAEC-PAD, SEC-MALS, IC) and a brief method report.
Fit-for-purpose profiling of natural or synthetic samples. Outputs: identity, purity, monosaccharide composition, linkages/branching, MW/dispersity, charge, and key functional metrics. Methods: HPAEC-PAD/GC-MS, methylation linkage analysis, 1D/2D NMR, MS/MS, SEC-MALS, CE/IC, FTIR, basic rheology. Deliverables: raw data, annotated spectra, SOPs, and actionable recommendations.
Creative Biolabs provides end-to-end anti-proteoglycan antibody development services that turn complex glycoconjugate biology into reliable assays and decision-ready data. Contact Our Team for More Information and to Discuss Your Project.
Reference
-
Walimbe, Tanaya, and Alyssa Panitch. "Proteoglycans in biomedicine: resurgence of an underexploited class of ECM molecules." Frontiers in Pharmacology 10 (2020): 1661. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fphar.2019.01661
For Research Use Only.
Related Services
